oth operating units and all Novo Nordisk ® Reported therapy area sales and growth for the first half of 2021 DKK billion 72 North America Operations 12% 30% International Operations 1% 34% Growth at CER 7% 60 48 13% 36 24 11% 12 0 Total 1 46% 24% GLP-1 6% -11% IO 44% NAO 27% IO 4% NAO 12% Insulin Obesity Biopharm World; NAO: North America Operations
Download PDF file